BioCentury
ARTICLE | Preclinical News

Sept. 12 Preclinical Quick Takes: Stephen Quake newco reveals epigenomic platform; plus Personal Genome, Summit and Biolife4D

September 12, 2019 10:34 PM UTC

Bluestar’s epigenomic platform IDs breast, pancreatic cancer
Bluestar Genomics Inc. (San Francisco, Calif.) showed it correctly identified breast and pancreatic cancers with areas under the curve of 0.89 and 0.95, respectively, with its machine learning algorithms that analyze blood levels of epigenomic marker 5-hydroxymethylcytosine (5hmC) at cancer type-associated loci. The company, which presented the data Tuesday at the Early Detection Research Network Scientific Workshop in Bethesda, was founded in 2016 based on IP developed by co-founder and serial entrepreneur Stephen Quake and licensed from Stanford University. CSO Sam Levy told BioCentury the company is focusing on stage 1 or earlier cancers, including those with tumor sizes smaller than 2 cm.

Liquid biopsy test detects MSI status, TMB...